<DOC>
	<DOC>NCT00060515</DOC>
	<brief_summary>The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.</brief_summary>
	<brief_title>RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease</brief_title>
	<detailed_description />
	<mesh_term>Mitochondrial Diseases</mesh_term>
	<criteria>Mitochondrial Disease</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
</DOC>